Transcatheter Technologies, a company out of Regensburg, Germany, announced that it’s developed a transfemoral version of its Trinity transcatheter aortic valve system. The valve is repositionable at any time during the implantation process to make sure a proper fit is achieved, even after full deployment.
The company claims the valve has excellent characteristics for preventing leaks. The anchoring system was designed to alleviate the chance of atrio-ventricular (AV) blockage.
“We will expand our platform technology with a transfemoral system to complete our truly repositionable Trinity TAVI system. The transfemoral Trinity system will have the same features as our transapical system,” said Wolfgang Goetz, M.D., Ph.D., CEO, a cardiac surgeon. “The tremendous advantage of Trinity is that even when the valve is completely expanded and anchored above the annulus—unlike currently marketed TAVI systems—the Trinity valve may still be repositioned, retrieved, or kept in the same position. This feature is absolutely unique to Trinity and the reason why we have positioned Trinity as the Third-Generation TAVI System.”
Here’s a company animation showing the mechanics of the Trinity valve implantation: